Fasting C-peptide in Gestational Diabetes Mellitus - Hasan, Md. Rakibul; Sultana, Nusrat; Hasan, Mashfiqul; Jahan, Sharmin; Hasanat, Muhammad Abul (medRxiv, 2024)
Introduction Insulin secretion and sensitivity are thought to vary in gestational diabetes mellitus (GDM) as well as in different trimesters within the same individual.Objectives To see the fasting serum C-peptide in subjects with GDM as an indicator of basal insulin secretion and to compare it to the normal glucose tolerance (NGT) control.Method This case-control study investigated and compared fasting serum C-peptide in 35 GDM subjects with 37, age, BMI, and trimester-matched control. GDM was diagnosed by WHO 2013 criteria. Plasma glucose was measured by the glucose oxidase method and C-peptide by a chemiluminescent immunometric assay.Result Fasting serum C-peptides were significantly higher in the GDM group than that of the NGT (NGT vs. GDM: 1.45±0.76 vs. 1.99±1.28, mean±SD, p=0.032), but no difference was observed between GDM and NGT with a BMI <25kg/m2 (NGT vs. GDM: 1.25±0.44 vs. 1.37±0.77, mean±SD, p=0.597). Within the NGT group, fasting C-peptide was similar with a BMI cut-off 25kg/m2 (<25 vs. ≥ 25: 1.25±0.44 vs. 1.61±0.94, p=0.159); however, within the GDM group, the fasting C-peptide was significantly higher with a BMI ≥25 kg/m2 (<25 vs. ≥ 25: 1.37±0.77 vs. 2.45±1.41, mean ±SD, p=0.011). We did not observe any trimester-specific difference in fasting C-peptide between the NGT and the GDM (NGT vs. GDM: 1.55±0.45 vs. 1.67±0.57, p=0.736; 1.43±0.95 vs. 2.13±1.10, p=0.085; 1.43±0.71 vs. 1.97±1.60, p= 0.204; ng/dl, mean ± SD, for 1st, 2nd, and 3rd trimester, respectively). Pearson correlation revealed BMI (r=0.389, p=0.001), Systolic BP (r=0.531, p<0.001), Diastolic BP (r=0.355, p=0.002), FPG (r=0.32, p=0.006) and 1hr PG on OGTT (r=0.423, p<0.001) had significant positive correlation with fasting C-peptide.Conclusion Fasting C-peptide increased significantly in GDM with BMI ≥25kg/m2, but not with <25kg/m2Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by University Research and Development, BSMMU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh gave ethical approval for this work. Protocol Reg. BSMMU/2016/2746, approved on 08-03-2016.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors